Live video webcast with moderated fireside chat with members from the CNS Pharmaceuticals management team and featuring Key Opinion Leader,

Samuel A. Goldlust

, MD, on

Thursday, April 14th

at

11:30 AM ET

HOUSTON


,


April 12, 2022


/PRNewswire/ —


CNS Pharmaceuticals, Inc.

(NASDAQ: CNSP)

(“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight event on

Thursday, April 14


^th

at

11:30 AM ET

.

For the spotlight event,

John Climaco

, CEO of CNS Pharmaceuticals will be joined by Key Opinion Leader

Samuel A. Goldlust

, MD, to discuss GBM, the unmet need and the work CNS Pharmaceuticals is doing to advance

Berubicin

for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

Dr. Goldlust is a leading Neuro-Oncologist who currently serves as the Pitkin Chair in Neuro-Oncology and Medical Director of the Brain and Spine Institute, John Theurer Cancer Center and an investigator in the Company’s global potentially pivotal study of Berubicin.

Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Anthracyclines, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents, are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin, was developed by Dr.

Waldemar Priebe

, Professor of Medicinal Chemistry at The

University of Texas

MD Anderson Cancer Center. The Company is currently conducting a potentially pivotal global study evaluating the efficacy and safety of Berubicin in the treatment of GBM.

A

live video webcast

of the presentation will be available on the

Events

page of the

Investors

section of the Company’s website (

cnspharma.com

). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Additionally, the Company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.

For more information, please visit

www.CNSPharma.com

, and connect with the Company on

Twitter

,

Facebook

, and

LinkedIn

.

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of the Company’s cash runway to extend until Q1 2022 and the timing of patient dosing to commence. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. “Risk Factors” in CNS’s most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

View original content to download multimedia:

https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-the-virtual-investor-glioblastoma-multiforme-gbm-spotlight-event-301523574.html

SOURCE CNS Pharmaceuticals, Inc.